Evidence mapPaperPMID 40098752Full record

ArticleIn silico pharmacology2025

Deciphering the the molecular mechanism of aloe-emodin in managing type II diabetes mellitus using network pharmacology, molecular docking, and molecular dynamics simulation approaches.

Samuel Baker Obakiro, Kenedy Kiyimba, Yahaya Gavamukulya, Richard Maseruka, Catherine Nabitandikwa, Ronald Kibuuka, Jalia Lulenzi, Tonny Wotoyitide Lukwago, Mercy Chebijira, Moses Opio and 7 more

Abstract read
In one paragraph

Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Samuel Baker ObakiroNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.ORCID https://orcid.org/0000-0001-9258-2519
Kenedy KiyimbaNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.ORCID https://orcid.org/0000-0001-8031-9051
Yahaya GavamukulyaNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.ORCID https://orcid.org/0000-0001-6031-1642
Richard MaserukaNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.ORCID https://orcid.org/0000-0002-0674-2107
Catherine NabitandikwaNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.
Ronald KibuukaNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.ORCID https://orcid.org/0009-0000-5265-4549
Jalia LulenziNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.
Tonny Wotoyitide LukwagoNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.
Mercy ChebijiraNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.
Moses OpioNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.ORCID https://orcid.org/0000-0003-1183-2307
Edeya Sharon TracyNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.
Dan KibuuleNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.
Richard Owor OrikoNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.ORCID https://orcid.org/0000-0002-0211-8833
Paul WaakoNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.
Angela MakayeThe University of Dodoma, P.O. Box 259, Dodoma, Tanzania.
Daniel M ShadrackSt John's University of Tanzania, P.O. Box 47, Dodoma, Tanzania.
Moses AndimaNatural Products Research and Innovation Centre, Busitema University, P.O. Box 1460, Mbale, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aloe-emodin (AE) has drawn interest due to its potential activity against type II diabetes mellitus (T2DM). However, the mechanisms underlying its antidiabetic activity are not well explored. Using network pharmacology, molecular docking and molecular dynamics simulation studies, we investigated its molecular mechanisms in the management of T2DM. Potential target genes of AE were predicted using the Swiss Target Prediction (http://www.swisstargetprediction.ch/) database. The GeneCards, OMIM and DisGeNET databases were used to compile a comprehensive list of genes associated with T2DM. A compound-disease-target network was constructed, and protein-protein interaction networks were analysed to identify hub genes. Finally, molecular docking and interaction analysis between AE and the identified proteins were performed using AutoDock tools. Investigation of AE targets and genes associated with T2DM identified 32 overlapping genes. Gene ontology studies revealed that AE may exert its anti-diabetic effects by modulating glucose metabolism and enhancing cellular response to glucose. Furthermore, KEGG pathway analysis suggested that AE influences these processes by targeting pathways related to apoptosis, insulin resistance, and T2DM signaling. The core target proteins identified were TNF, ALB, TP53, PPARG, BCL2, CASP3, and EGFR. AE interaction with each of these proteins exhibited a binding energy of > - 5 kcal/mol, with TNF showing the lowest binding energy (- 7.75 kcal/mol). Molecular dynamics simulation further validated the molecular docking results with TNF and EGFR exhibiting a strong affinity for AE and forming stable interactions. AE exerts its antidiabetic activity through multiple mechanisms, with the most significant being the amelioration of pancreatic β-cell apoptosis by binding to and inhibiting the actions of TNFα. Further cellular and molecular studies are needed to validate these findings. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00337-1.

Indexed as

Aloe emodinMolecular dockingNetwork pharmacologyType II diabetes mellitus

Identifiers

PMID40098752
PMCPMC11910477

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.